Gilead Sciences Inc.

77.60+3.20+4.30%Vol 12.93M1Y Perf 20.37%
Jun 4th, 2020 15:56 DELAYED
BID77.61 ASK77.64
Open74.12 Previous Close74.40
Pre-Market74.10 After-Market77.26
 -0.30 -0.40%  -0.28 -0.36%
Target Price
82.11 
Analyst Rating
Hold 2.57
Potential %
5.81 
Finscreener Ranking
★+     44.85
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★+     54.81
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★     52.50
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
★★★+     52.08
Market Cap97.34B 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
66.63 
Earnings Date
30th Apr 2020

Today's Price Range

73.9478.18

52W Range

60.8985.97

5 Year PE Ratio Range

5.9025.50

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
-0.30%
1 Month
-1.95%
3 Months
1.93%
6 Months
17.70%
1 Year
20.37%
3 Years
18.51%
5 Years
-31.39%
10 Years
350.59%

TickerPriceChg.Chg.%
GILD77.603.20004.30
AAPL322.32-2.8000-0.86
GOOG1 412.18-24.2000-1.68
MSFT182.92-2.4400-1.32
XOM49.10-0.1400-0.28
WFC30.361.53005.31
JNJ146.73-1.9200-1.29
FB226.29-3.8700-1.68
GE7.740.38005.16
JPM106.442.17002.08
Financial StrengthValueIndustryS&P 500US Markets
2.80
3.40
0.50
1.09
5.90
Leverage Ratio 2.80
ProfitabilityValueIndustryS&P 500US Markets
79.40
25.50
31.60
48.40
21.72
RevenueValueIndustryS&P 500US Markets
22.72B
18.11
-7.54
-6.59
DividendsValueIndustryS&P 500US Markets
3.62
2.72
8.71
-
Payout ratio116.00
Earnings HistoryEstimateReportedSurprise %
Q01 20201.471.6814.29
Q04 20191.581.10-30.38
Q03 20191.661.65-0.60
Q02 20191.681.722.38
Q01 20191.531.679.15
Q04 20181.611.34-16.77
Q03 20181.561.708.97
Q02 20181.471.7519.05
Earnings Per EndEstimateRevision %Trend
6/2020 QR1.583.95Positive
9/2020 QR1.603.23Positive
12/2020 FY6.395.62Positive
12/2021 FY6.595.10Positive
Next Report Date-
Estimated EPS Next Report1.47
Estimates Count7
EPS Growth Next 5 Years %3.50
Volume Overview
Volume12.93M
Shares Outstanding1.25B
Trades Count127.37K
Dollar Volume1.19B
Avg. Volume19.92M
Avg. Weekly Volume16.01M
Avg. Monthly Volume12.80M
Avg. Quarterly Volume22.04M

Gilead Sciences Inc. (NASDAQ: GILD) stock closed at 77.54 per share at the end of the most recent trading day (a 4.3% change compared to the prior day closing price) with a volume of 14.73M shares and market capitalization of 97.34B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 11000 people. Gilead Sciences Inc. CEO is Daniel O¿Day.

The one-year performance of Gilead Sciences Inc. stock is 20.37%, while year-to-date (YTD) performance is 19.42%. GILD stock has a five-year performance of -31.39%. Its 52-week range is between 60.89 and 85.97, which gives GILD stock a 52-week price range ratio of 66.63%

Gilead Sciences Inc. currently has a PE ratio of 20.00, a price-to-book (PB) ratio of 4.42, a price-to-sale (PS) ratio of 4.15, a price to cashflow ratio of 11.00, a PEG ratio of 2.32, a ROA of 8.10%, a ROC of 11.99% and a ROE of 22.55%. The company’s profit margin is 21.72%, its EBITDA margin is 31.60%, and its revenue ttm is $22.72 Billion , which makes it $18.11 revenue per share.

Of the last four earnings reports from Gilead Sciences Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $1.47 for the next earnings report. Gilead Sciences Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Gilead Sciences Inc. is Hold (2.57), with a target price of $82.11, which is +5.81% compared to the current price. The earnings rating for Gilead Sciences Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Gilead Sciences Inc. has a dividend yield of 3.62% with a dividend per share of $2.72 and a payout ratio of 116.00%.

Gilead Sciences Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 9.91, ATR14 : 2.73, CCI20 : 35.40, Chaikin Money Flow : 0.07, MACD : -0.58, Money Flow Index : 57.16, ROC : 7.19, RSI : 53.43, STOCH (14,3) : 89.12, STOCH RSI : 0.96, UO : 60.15, Williams %R : -10.88), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Gilead Sciences Inc. in the last 12-months were: Andrew Dickinson (Option Excercise at a value of $0), Brett A. Pletcher (Option Excercise at a value of $4 204 162), Brett A. Pletcher (Sold 194 286 shares of value $13 104 895 ), Daniel O'Day (Option Excercise at a value of $0), Diane E. Wilfong (Option Excercise at a value of $762 211), Diane E. Wilfong (Sold 12 264 shares of value $982 220 ), Gayle E. Wilson (Option Excercise at a value of $426 364), Gayle E. Wilson (Sold 21 720 shares of value $1 470 878 ), Harish Manwani (Option Excercise at a value of $0), John F. Cogan (Option Excercise at a value of $426 364), John F. Cogan (Sold 21 720 shares of value $1 679 500 ), Kevin E. Lofton (Option Excercise at a value of $426 364), Per Wold-Olsen (Option Excercise at a value of $961 675), Per Wold-Olsen (Sold 46 910 shares of value $3 192 734 ), Richard J. Whitley (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (23.81 %)
7 (31.82 %)
10 (45.45 %)
Moderate Buy
1 (4.76 %)
2 (9.09 %)
1 (4.55 %)
Hold
14 (66.67 %)
12 (54.55 %)
10 (45.45 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (4.76 %)
1 (4.55 %)
1 (4.55 %)
Summary RatingHold
2.57
Moderate Buy
2.36
Moderate Buy
2.14

Gilead Sciences Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition boosted Gilead's exposure to cell therapy in oncology.

CEO: Daniel O¿Day

Teplephone: +1 650 574-3000

Address: 333 Lakeside Drive, Foster City 94404, CA, USA

Number of employees: 11 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

49%51%

Bearish Bullish

44%56%

Bearish Bullish

59%41%

News

Stocktwits